Effects of probiotics on atopic dermatitis: a randomised controlled trial.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Weston S;Weston S; Halbert A; Richmond P; Prescott SL
  • Source:
    Archives of disease in childhood [Arch Dis Child] 2005 Sep; Vol. 90 (9), pp. 892-7. Date of Electronic Publication: 2005 Apr 29.
  • Publication Type:
    Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: BMJ Pub. Group [etc.] Country of Publication: England NLM ID: 0372434 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2044 (Electronic) Linking ISSN: 00039888 NLM ISO Abbreviation: Arch Dis Child Subsets: MEDLINE
    • Publication Information:
      Publication: London :, BMJ Pub. Group [etc.]
      Original Publication: London : British Medical Association
    • Subject Terms:
    • Abstract:
      Background: The aim of the study was to investigate the effects of probiotics on moderate or severe atopic dermatitis (AD) in young children.
      Methods: Fifty six children aged 6-18 months with moderate or severe AD were recruited into a randomised double blind placebo controlled trial in Perth, Western Australia; 53 children completed the study. The children were given a probiotic (1x10(9)Lactobacillus fermentum VRI-033 PCC; Probiomics) or an equivalent volume of placebo, twice daily for 8 weeks. A final assessment at 16 weeks was performed.
      Results: The main outcome measures were severity and extent of AD at the end of the study, as measured by the Severity Scoring of Atopic Dermatitis (SCORAD) index. The reduction in the SCORAD index over time was significant in the probiotic group (p = 0.03) but not the placebo group. Significantly more children receiving probiotics (n = 24, 92%) had a SCORAD index that was better than baseline at week 16 compared with the placebo group (n = 17, 63%) (p = 0.01). At the completion of the study more children in the probiotic group had mild AD (n = 14, 54%) compared to the placebo group (n = 8, 30%).
      Conclusion: Supplementation with probiotic L fermentum VRI-003 PCC is beneficial in improving the extent and severity of AD in young children with moderate or severe disease.
    • Comments:
      Comment in: Arch Dis Child. 2005 Sep;90(9):881-2. (PMID: 16113122)
      Comment in: J Pediatr. 2006 Jan;148(1):143-4. (PMID: 16440481)
      Comment in: Arch Dis Child. 2006 Mar;91(3):276; author reply 276. (PMID: 16492896)
      Comment in: Arch Dis Child. 2006 Apr;91(4):373. (PMID: 16551799)
      Comment in: Arch Dermatol. 2006 Sep;142(9):1201-3. (PMID: 16983007)
    • References:
      Clin Exp Allergy. 2000 Sep;30(9):1230-4. (PMID: 10971468)
      J Immunol. 1997 Aug 15;159(4):1739-45. (PMID: 9257835)
      Br J Dermatol. 1998 Jan;138(1):107-13. (PMID: 9536231)
      Dermatology. 1997;195(1):10-9. (PMID: 9267730)
      Clin Exp Allergy. 2000 Nov;30(11):1590-6. (PMID: 11069568)
      Clin Exp Allergy. 2000 Nov;30(11):1604-10. (PMID: 11069570)
      Br J Dermatol. 2001 Mar;144(3):514-22. (PMID: 11260008)
      Lancet. 2001 Apr 7;357(9262):1057-9. (PMID: 11297952)
      Clin Infect Dis. 2002 Mar 1;34(5):620-6. (PMID: 11810601)
      Arch Dis Child. 2002 Jul;87(1):26-9. (PMID: 12089117)
      Pharmacoeconomics. 2003;21(2):105-13. (PMID: 12515572)
      J Allergy Clin Immunol. 2003 Feb;111(2):389-95. (PMID: 12589361)
      Pediatrics. 2003 Mar;111(3):608-16. (PMID: 12612244)
      Int J Med Microbiol. 2003 Apr;293(1):77-86. (PMID: 12755368)
      Allergy. 2003 Jun;58(6):461-71. (PMID: 12757444)
      FEMS Immunol Med Microbiol. 2003 Sep 22;38(2):165-72. (PMID: 13129651)
      J Allergy Clin Immunol. 2003 Oct;112(4):740-6. (PMID: 14564354)
      Br J Dermatol. 2003 Nov;149(5):1023-8. (PMID: 14632809)
      J Allergy Clin Immunol. 2004 May;113(5):925-31. (PMID: 15131576)
      J Allergy Clin Immunol. 1997 Feb;99(2):179-85. (PMID: 9042042)
      N Engl J Med. 2000 Aug 24;343(8):538-43. (PMID: 10954761)
    • Accession Number:
      0 (Anti-Allergic Agents)
    • Publication Date:
      Date Created: 20050503 Date Completed: 20050913 Latest Revision: 20181113
    • Publication Date:
      20240104
    • Accession Number:
      PMC1720555
    • Accession Number:
      10.1136/adc.2004.060673
    • Accession Number:
      15863468